Oculis Holding
OCS
About: Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Employees: 49
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
15% more funds holding
Funds holding: 20 [Q1] → 23 (+3) [Q2]
1.32% more ownership
Funds ownership: 10.37% [Q1] → 11.69% (+1.32%) [Q2]
5% more capital invested
Capital invested by funds: $94.7M [Q1] → $99.1M (+$4.36M) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
Needham
Serge Belanger
|
$36
|
Buy
Initiated
|
27 Aug 2025 |
|
HC Wainwright & Co.
Yi Chen
|
$33
|
Buy
Maintained
|
22 Aug 2025 |
Financial journalist opinion
Based on 13 articles about OCS published over the past 30 days
